Search

In 2014, tofacitinib, a target-specific, synthetic disease modifying anti rheumatic drug (DMARD) and a selective inhibitor of Janus kinase (JAK) was approved for use in Brazil. This position paper aims to update the recommendations of the Brazilian Society of Rheumatology (SBR) on the treatment of rheumatoid arthritis (RA) in Brazil, specifically regarding the use of target-specific synthetic DMARDs. The method of this recommendation consisted of a literature review of scientific papers held on the Medline database. After this review, a text was produced, answering questions in Pico structure, considering efficacy and safety issues of tofacitinib use for RA treatment in different scenarios (such as first-line treatment after failure with methotrexate [MTX] or other conventional synthetic DMARDs after failure with biological therapy). Based on existing evidence, and considering the available data on efficacy, safety and cost of medications available to treat the disease in Brazil, the RA Commission of SBR, after a process of discussion and voting on proposals, established the following position on the use of tofacitinib for treatment of RA in Brazil: “Tofacitinib, alone or in combination with MTX, is an alternative for RA patients with moderate or high activity after failure of at least two different synthetic DMARDs and one biological DMARD.” The level of agreement with this recommendation was 7.5.This position may be reviewed in the coming years, in the face of a greater experience with the use of this medication.

Resumo Em 2014, o tofacitinibe, um medicamento modificador do curso da doença (MMCD) sintético, alvo-específico, inibidor seletivo das Janus quinases (JAK), foi aprovado para uso no Brasil. Este documento de posicionamento tem o objetivo de atualizar as recomendações da Sociedade Brasileira de Reumatologia (SBR) sobre o tratamento da artrite reumatoide (AR) no Brasil, especificamente com relação ao uso de MMCD sintéticos alvo-específicos. O método dessa recomendação incluiu revisão bibliográfica de artigos científicos, feita na base de dados Medline. Após a revisão, foi produzido um texto, que responde a perguntas na estrutura Pico, e considera questões de eficácia e segurança do uso do tofacitinibe para tratamento de AR em diferentes situações (como primeira linha de tratamento, após falha ao metotrexato [MTX] ou outros MMCD sintéticos convencionais, após falha da terapia biológica). Com base nas evidências existentes, e considerando os dados disponíveis sobre eficácia, segurança e custo das medicações disponíveis para tratamento da doença no Brasil, a Comissão de AR da SBR, após processo de discussão e votação de propostas, estabeleceu o seguinte posicionamento sobre o uso de tofacitinibe para o tratamento da AR no Brasil: “Tofacitinibe, em monoterapia ou em associação ao MTX, é uma opção para os pacientes com AR em atividade moderada ou alta, após falha de pelo menos dois esquemas com diferentes MMCD sintéticos e um esquema de MMCD biológico”. O grau de concordância com essa recomendação foi 7,5. Esse posicionamento poderá ser revisto nos próximos anos, com a maior experiência adquirida com o uso do medicamento. Abstract In 2014, tofacitinib, a target-specific, synthetic disease modifying anti rheumatic drug (DMARD) and a selective inhibitor of Janus kinase (JAK) was approved for use in Brazil. This position paper aims to update the recommendations of the Brazilian Society of Rheumatology (SBR) on the treatment of rheumatoid arthritis (RA) in Brazil, specifically regarding the use of target-specific synthetic DMARDs. The method of this recommendation consisted of a literature review of scientific papers held on the Medline database. After this review, a text was produced, answering questions in Pico structure, considering efficacy and safety issues of tofacitinib use for RA treatment in different scenarios (such as first-line treatment after failure with methotrexate [MTX] or other conventional synthetic DMARDs after failure with biological therapy). Based on existing evidence, and considering the available data on efficacy, safety and cost of medications available to treat the disease in Brazil, the RA Commission of SBR, after a process of discussion and voting on proposals, established the following position on the use of tofacitinib for treatment of RA in Brazil: “Tofacitinib, alone or in combination with MTX, is an alternative for RA patients with moderate or high activity after failure of at least two different synthetic DMARDs and one biological DMARD.” The level of agreement with this recommendation was 7.5. This position may be reviewed in the coming years, in the face of a greater experience with the use of this medication.

ResumoPolicondrite recidivante é uma condição rara, imunomediada, caracterizada por episódios de inflamação de estruturas cartilaginosas, principalmente orelhas, nariz, articulações e sistema respiratório. Acomete também estruturas ricas em proteoglicanos como olhos, coração, vasos sanguíneos e ouvido interno. Em torno de 1/3 dos casos apresentam associação com outras doenças como vasculites sistêmicas, doenças do tecido conectivo ou síndrome mielodisplásica. Desordens do ouvido interno ocorrem em 40%‐50% dos pacientes. Perda auditiva profunda é rara. O objetivo do estudo foi descrever o caso de uma paciente com diagnóstico de policondrite recidivante associado à perda auditiva severa bilateral e manifestações clínicas de vasculite sistêmica. Este trabalho reforça a importância do diagnóstico precoce e do tratamento imediato em caso de manifestações severas da doença.AbstractRelapsing polychondritis is an uncommon, immune‐mediated condition characterized by episodes of inflammation of cartilaginous structures, especially the ears, nose, joints and respiratory tract. RP also affects proteoglycan‐rich structures such as the eyes, heart, blood vessels and inner ear. Around one third of cases are associated with other diseases such as vasculitides, connective tissue diseases or myelodysplastic syndrome. Disorders of the inner ear occur in 40‐50% of patients. Profound hearing loss is rare. The aim of this study was to describe the case of a patient with relapsing polychondritis associated with severe bilateral hearing loss and clinical manifestations of systemic vasculitis. This study reinforces the importance of an early diagnosis and immediate treatment in case of severe manifestations of the disease.

Dermatophytes are fungi capable of invading keratinized tissues. Isolation of the fungus with the culture is essential to guide the treatment, because there are more resistant species like Microsporum canis. The chronic use of corticosteroids leads to the deregulation of immunity, promoting atypical manifestations of infections. Topical antifungal therapy is often insufficient, requiring systemic medications. We describe the case of a patient undergoing systemic corticosteroid therapy with a large figurate lesion who presented complete response to exclusively topical treatment.

Relatamos aqui o caso de um paciente masculino de 30 anos de idade, sexo masculino, com achados clínicos típicos da síndrome de Behçet (SB) e da policondrite recidivante (PR) sem, no entanto, preencher completamente os critérios de classificação para nenhuma das entidades isoladamente. O termo síndrome MAGIC (Mouth And Genital ulcers with Inflamed Cartilage) tem sido usado para classificar pacientes semelhantes. Uma breve revisão dos casos previamente relatados também é apresentada.We describe a 30 years old man with typical features of both Behçet's syndrome and relapsing polychondritis but neither complete classification criteria. The term MAGIC syndrome (Mouth And Genital ulcers with Inflamed Cartilage) has been used to describe similarly affected patients. We present a brief review of previously reported cases.

Relapsing polychondritis is an uncommon, immune-mediated condition characterized by episodes of inflammation of cartilaginous structures, especially the ears, nose, joints and respiratory tract. RP also affects proteoglycan-rich structures such as the eyes, heart, blood vessels and inner ear. Around one third of cases are associated with other diseases such as vasculitides, connective tissue diseases or myelodysplastic syndrome. Disorders of the inner ear occur in 40–50% of patients. Profound hearing loss is rare. The aim of this study was to describe the case of a patient with relapsing polychondritis associated with severe bilateral hearing loss and clinical manifestations of systemic vasculitis. This study reinforces the importance of an early diagnosis and immediate treatment in case of severe manifestations of the disease.

Relatamos aqui o caso de um paciente masculino de 30 anos de idade, sexo masculino, com achados clinicos tipicos da sindrome de Behcet (SB) e da policondrite recidivante (PR) sem, no entanto, preencher completamente os criterios de classificacao para nenhuma das entidades isoladamente. O termo sindrome MAGIC (Mouth And Genital ulcers with Inflamed Cartilage) tem sido usado para classificar pacientes semelhantes. Uma breve revisao dos casos previamente relatados tambem e apresentada.

Two patients with neuropathic arthropathy (NA) of hands and wrists due to cervical syringomyelia are described. Articular deformities resembling rheumatoid arthritis (RA) were present in both cases. RA was misdiagnosed in the first case, leading to incorrect treatment with iatrogenic consequences, and there was real coexistence of RA and NA in the second one. Physicians must be aware of this rare condition in the differential diagnosis of wrist and hand deformities.